Novartis schreibt 12. Oppenheim-Förderpreis für Multiple Sklerose aus
Jetzt bewerben! Förderprogramm 2021 der pbm Academy Stiftung: Best-Practices im…
Palliativmediziner Thöns erhält Deutschen Schmerzpreis
Jetzt bewerben: RheumaPreis 2021 – positive Vorbilder gesucht!
Gewinner des Teva Better Days Awards stehen fest
Pflegeforum zur COVID-19-Impfung: Impulsvortrag, Diskussionsrunde, Beratungshotline – immer donnerstags ab…
Der Deutsche Schmerz- und Palliativtag 2021 findet online statt: 9.…
BGW forum – Online-Kongress: “Sicher und gesund in der Pflege”…
4./5. März 2021: „Parkinson und Bewegungsstörungen – Highlights Digital“ am…
Online-Experten-Talk „Die ersten 1.000 Tage – Basis für ein gesundes…
Researchers predict onset of Alzheimer’s disease with 85 percent accuracy
Major step towards Alzheimer’s blood test
Cardiff, UK (August 31, 2016) – A research team, led by Cardiff University, has made a significant step towards the development of a simple blood test to predict the onset of Alzheimer’s disease. Funded by the Alzheimer’s Society, the group of researchers from Cardiff University, King’s College London and the University of Oxford studied blood from 292 individuals with the earliest signs of memory impairment and found a set of biomarkers (indicators of disease) that predicted whether or not a given individual would develop Alzheimer’s disease.
Professor Paul Morgan, Director of Cardiff University’s Systems Immunity Research Institute, said: "Our research proves that it is possible to predict whether or not an individual with mild memory problems is likely to develop Alzheimer’s disease over the next few years. We hope to build on this in order to develop a simple blood test that can predict the likelihood of developing Alzheimer’s disease in older people with mild, and possibly innocent, memory impairment."
The study took blood samples from individuals presenting with very common symptoms of memory impairment and measured a large number of proteins belonging to a part of the immune system which is known to drive inflammation and has previously been implicated in brain diseases. When the individuals were re-assessed a year later, about a quarter had progressed to Alzheimer’s disease and three of the proteins measured in their blood showed significant differences from the blood of participants that did not go on to develop the disease.
Professor Morgan added: "Alzheimer’s disease affects around 520,000 people in the UK and this number is continually growing as the population ages. As such it is important that we find new ways to diagnose the disease early, giving us a chance to investigate and instigate new treatments before irreversible damage is done."
These new findings laid the groundwork for a much larger, ongoing study funded by the Wellcome Trust and involving several UK Universities and Pharmaceutical companies that will seek to replicate the findings and refine the test.
- The paper ‘Complement Biomarkers as predictors of disease progression in Alzheimer’s disease’ is published in Journal of Alzheimer’s Disease. http://content.iospress.com/articles/journal-of-alzheimers-disease/jad160420
Cardiff University , 31.08.2016 (tB).